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Dear Editor,
In early breast cancer, the prognostic value of the num-
ber of macroscopically metastasized axillary nodes has 
been recognized in earlier reports [1]. However, the 
impact of microscopic tumour cell deposits on the sur-
vival outcome of early breast cancer patients is still 
debated [2]. This issue has gained increasing attention 
since the implementation of sentinel node biopsy in axil-
lary node staging for tailoring breast cancer treatments, 
and the status of the single resected node would deter-
mine the clinical decision of whether or not to perform 
the axillary lymph node dissection [3]. Moreover, this 
issue raises more questions on whether to administer 
primary or adjuvant systemic treatment for patients with 
lymph nodes bearing isolated tumour cells (pN0[i+]) 
or micrometastases (pN1mi). Despite the wide debate 
on the clinical treatment dilemma encountered by early 
breast cancer patients with microscopic tumour cell 
deposits, the biology underlying different pathologi-
cal presentations at microscopic level (pN0, pN0[i+], 
pN1mi) and the disease outcomes remain poorly known. 
In an attempt to shed some light on this topic, we have 
analyzed, in the context of dormancy-based metastasis 
development model [4], early breast cancer patients con-
ventionally classified as pN0 (tumour foci with largest 
diameter ≤ 2 mm) [5] by systematically reassessing their 
tumor recurrence dynamics following primary tumour 
resection at a single institution.
The analyzed database [5] comprised of 377 early 
breast cancer patients who underwent mastectomy (67%) 
or conservative surgery (33%) and staged as pN0, based 
on the 6th edition of the Union for International Cancer 
Control/American Joint Committee on Cancer (UICC/
AJCC) TNM classification [6]. Adjuvant systemic treat-
ment was administered to 29% (chemotherapy, 8% and 
hormone therapy, 21%) of the patients, whereas 55% 
received surgery only and 16% had incomplete records. 
This study cohort had a median follow-up period of up to 
8 years (range 1–13 years).
A total of 6676 axillary lymph nodes were surgically 
harvested, step-sectioned at every 200  μm (about 250 
sections per patient), stained with haematoxylin and 
eosin (Fig. 1a, c), and reassessed by immunohistochemi-
cal analysis for cytokeratin expression (AE1-AE3-PCK26 
antibody, Ventana, Tucson, AZ) (Fig.  1b, d). Immuno-
histochemistry was done with an automated immu-
nostainer (Ventana NEXES Medical System, Tucson, AZ) 
run with Ventana kits (Strasbourg, France). Lymph node 
sections were independently examined by two patholo-
gists, with the help of a computerized image analyzer 
morphometric system (EUREKA, Menarini Diagnostic, 
Florence, Italy). Accordingly, the pN0 patients were re-
classified as: (1) pN0(i−), no detectable tumour deposits; 
(2) pN0(i+) (nanometastases), isolated tumour cells or 
foci with largest diameter ≤ 0.2 mm, (Fig. 1a, b); and (3) 
pN1mi (micrometastases), tumour foci with the largest 
diameter being between 0.2 and 2 mm (Fig. 1c, d). Clini-
cal events such as tumor recurrence (local or distant), the 
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occurrence of second primary (including contralateral 
breast primary), and death, occurring within the median 
follow-up time, were examined (Table 1). The recurrence 
dynamics was investigated by estimating the cause-spe-
cific hazard rates, i.e., the rates of recurrence of a specific 
event at a certain follow-up time. To estimate the hazard 
rate at different follow-up times, a discretization of the 
time axis in 6-month units was applied (therefore haz-
ard rates were estimated in recurrences/6  months) and 
to obtain a smoothed pattern of the hazard rate values a 
kernel estimator was adopted [7]. This smoothed curve is 
graphically presented (Fig. 1e).
In spite of the limited number of events and patients 
at risk, the hazard rate curves for recurrence (Fig.  1e) 
show that, in comparison to the recurrence risk of 
pN0(i−) patients, that of pN0(i+) patients was relatively 
similar during the first 2  years but displayed a definite 
level increase afterwards, while that of pN1mi patients 
demonstrated an early peak followed by a second peak 
between at about 60 months postoperatively.
The differences in recurrence dynamics, as dem-
onstrated with hazard rate curves, observed between 
the different subcategories of pN0 early breast can-
cer patients in this study can be interpretable using the 
model context of tumour dormancy in specific micro-
metastatic phases and the occurrence of surgery-related 
events which have accelerated the metastatic process [4]. 
The main concept underlying this model is that meta-
static foci undergo dormant states, such as single cells in 
the  G0 phase of their mitotic cycle, nests containing non-
dividing cells, and micrometastases lacking angiogenesis, 
therefore they are unable to grow to larger than the size 
of 1–2 mm. Sequential transitions between microscopic 
dormant states eventually may result in the progressive 
appearance of metastases when they exceed the clini-
cal detection threshold level. Furthermore, the surgical 
removal of the primary tumour, the presence of which 
constrains the development of its microscopic metas-
tases [4], may unlock subclinical tumour dormant foci, 
thus inducing a sudden acceleration of the metastatic 
process which manifests during the follow-up, but at 
different time intervals based on the number of macro-
scopically non-visible proportions of single dormant cells 
and avascular micrometastases. These may have resulted 
in the different recurrence peaks observed between the 
pN0(i−), pN0(i+) and pN1mi subgroups; paralleling to 
the number and sequence of metastatic dormancy states. 
In particular, the early metastasis risk is associated to the 
sudden switch of angiogenesis in micrometastases, which 
may be related to surgical manoeuvre, whereas smaller 
nanometastases need more time to attain the clinical 
level for visible metastases and thereby display a longer 
period of dormancy [4]. Therefore, consistently with the 
lymph node staging, the behavior of hazard rate curves 
for different subcategories of pN0 early breast cancer 
patients shown in Fig.  1e suggests the possibility that 
subclinical metastases in pN0(i+) patients may be mostly 
comprised of single  G0 cells or nests containing a few 
non-dividing cells, whereas in the pN1mi subcategory 
avascular microscopic foci mostly prevail.
The different dynamics of disease recurrence in patients 
with pN0(i−), pN0(i+) and pN1mi breast cancer (Fig. 1e) 
support the notion that the axillary nodal tumour burden, 
which is a recognized quantitative marker of the recur-
rence risk at macroscopic level, is also a prognostic factor 
at microscopic level. This extension of the prognostic role 
of nodal involvement is revealed by the association of the 
pathologic findings with the corresponding recurrence 
hazard rate patterns. This finding suggests that nodal 
nanometastases can indicate the presence of tumour foci 
in early dormant states, whereas nodal micrometastases 
point to dormancy conditions being much nearer to a 
metastatic-probable clinical manifestation threshold that 
is reached soon after being surgically stimulated, as has 
been found to occur in breast cancer patients for whom 
axillary nodes are macroscopically invaded [4]. Results of 
the present analyses suggest a correlation between axil-
lary tumour burden and metastatic conditions, starting 
(See figure on previous page.)
Fig. 1 Pathological illustrations of lymph node occult metastases and the different dynamics of disease recurrence in patients with pN0(i−), 
pN0(i+) and pN1mi early breast cancer. a–d Examples of lymph node occult metastases from early breast cancer patients analyzed by haematoxylin 
and eosin (H&E) staining and immunohistochemistry (IHC). Consecutive sections stained by H&E (a, c) and by IHC (b, d). The location of the single 
tumour cells is indicated by arrows. Panels a and b, lymph node pN0(i+) (nanometastases); c, d lymph node pN1mi (micrometastases). Original 
magnification 20× objective. e, Hazard rate for recurrence pattern for the investigated patients. There were 328 early breast cancer patients lymph 
nodes pathologically diagnosed as pN0(i−), 24 as pN0(i+) and 25 as pN1mi. The hazard curve of the pN1mi subcategory displays the usual 
recurrence pattern as previously observed for breast cancer patients diagnosed with pN1 and pN2 diseases, thereby demonstrating an early peak at 
the second year and a further increase at about 60 months. By contrast, the recurrence risk curve of pN0(i+) patients, after a relatively stable period 
during the first 2 years, displays a steady increase and then a plateau-like trend. The recurrence risk pattern for pN0(i−) patients remains largely 
stable with a hazard rate of about 0.01 recurrence/6 months. pN, pathologically diagnosed nodal subcategories; pN0(i−), no detectable tumor 
deposits; pN0(i+), lymph nodes containing isolated tumor cells (nanometastases); pN1mi, lymph nodes containing tumour foci with the largest 
diameter ranging between 0.2 and 2 mm (micrometastases)
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at microscopic level, thus supporting the concept that 
axillary lymph nodes may be viewed as accessible sites 
to assess the biological status of subclinical metastatic 
deposits in the host. However, such a hypothesis deserves 
further validation.
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Table 1 First appearance of clinical events observed during the follow-up period
The numbers in parentheses represent events occurred within the median follow-up time of 8 years
pN, pathologically diagnosed nodal subcategories; pN0(i−), undetectable tumor deposits; pN0(i+), lymph nodes containing isolated tumor cells (nanometastases); 
pN1mi, lymph nodes containing tumour foci with the largest diameter ranging between 0.2 mm and 2 mm (micrometastases)
a Other tumours, unrelated to “early breast cancer”, which occured after its diagnosis
Events Undetectable metastases
[pN0(i−), n = 328]
Nanometastases
[pN0(i+), n = 24]
Micrometastases
[pN1mi, n = 25]
Local recurrence 20 (17) 3 (3) 5 (4)
Contralateral breast primary 10 (6) 1 (0) 1 (1)
Second  primariesa 19 (15) 3 (3) 2 (2)
Death 46 (41) 4 (4) 3 (2)
Metastases 29 (25) 7 (6) 4 (3)
Total events 124 (104) 18 (16) 15 (12)
